Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
QuintilesIMS
Chinese Patent Office
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson
Fish and Richardson
Medtronic
Mallinckrodt

Generated: January 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208603

« Back to Dashboard

NDA 208603 describes ARYMO ER, which is a drug marketed by Egalet and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ARYMO ER profile page.

The generic ingredient in ARYMO ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 208603
Tradename:ARYMO ER
Applicant:Egalet
Ingredient:morphine sulfate
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 208603
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 208603
Suppliers and Packaging for NDA: 208603
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603 NDA Egalet US Inc. 69344-111 69344-111-11 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (69344-111-11)
ARYMO ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 208603 NDA Egalet US Inc. 69344-211 69344-211-11 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (69344-211-11)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength15MG
Approval Date:Jan 9, 2017TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 1, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Patent:➤ Try a Free TrialPatent Expiration:Jul 1, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength30MG
Approval Date:Jan 9, 2017TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 1, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Express Scripts
UBS
Healthtrust
Julphar
QuintilesIMS
Daiichi Sankyo
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.